SDZ-ADL and reference adalimumab (ref-ADL) demonstrated equivalent efficacy (in terms of DAS28-CRP score change) in patients with moderate to severe active rheumatoid arthritis who had an inadequate response to disease-modifying anti-rheumatic drugs. Equivalent efficacy was also shown in terms of DAS28-CRP, ACR20/50/70 response rates, EULAR responses and Boolean remission rates.

The immunogenicity and safety profile of SDZ-ADL and ref-ADL were similar, and local tolerability of the injections was equally good. Switching from ref-ADL to SDZ-ADL did not have any negative impact on the safety or immunogenicity of adalimumab treatment.